Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1482 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Mengli Tian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Clinical Trial Center, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huz…. Hauptthemen laut MEDLINE: Dipeptidyl-Peptidase IV Inhibitors, Drugs, Generic, Pyrrolidines, Vildagliptin. Die Arbeit nennt 19 Literaturangaben.
Abstract (Originalsprache)
A randomized, open‐label, 2‐period, 2‐sequence crossover study was conducted to evaluate the pharmacokinetics and bioequivalence of 2 oral formulations of vildagliptin tablets under both fasting and fed conditions in healthy Chinese subjects. A total of 56 healthy subjects were randomized to receive a single 50‐mg dose of either a generic vildagliptin tablet (T) or the reference formulation (R). The washout period was 3 days. Blood samples were collected up to 24 hours postdosing during each period and analyzed for vildagliptin using liquid chromatography‐tandem mass spectrometry (LC‐MS/MS). The 90% confidence intervals for the geometric mean ratios (T:R) of maximum serum concentration, area under the serum concentration‐time curve from time 0 to the last measurable concentration, and area under the serum concentration‐time curve from time 0 to infinity were all within the predefined bioequivalence range of 80%‐125%. This indicates that the generic and reference formulations are bioequivalent under both fasting and fed states. All adverse events reported were mild and transient. High‐fat meals delayed absorption and reduced the maximum peak concentration of both formulations; however, they did not affect the overall exposure. Therefore, vildagliptin can be taken without regard to meals.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Clinical Trial Center, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.
- Zhejiang Huahai Pharmaceutical Co., Ltd., Linhai, Zhejiang, China.
- Chengdu Finelyse Pharmaceutical Technology Co., Ltd., Sichuan, China.
Zitieren
APA
Tian, M., Ye, L., Liang, B., Chen, Y., Mei, J., Zhao, Z., Guo, X., Xu, M., Zhang, J., & Yang, S. (2025). Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1482
Vancouver
Tian M, Ye L, Liang B, Chen Y, Mei J, Zhao Z, et al. Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1482
BibTeX
@article{Tian2025,
author = {Tian, Mengli and Ye, Libing and Liang, Binhong and Chen, Yingrong and Mei, Jue and Zhao, Zhouming and Guo, Xiaodi and Xu, Min and Zhang, Jingyao and Yang, Shuixin},
title = {Pharmacokinetics and Bioequivalence of 2 Oral Formulations of Vildagliptin in Healthy Chinese Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1482}
}
EUVIMED